Ohr Pharmaceutical is an
ophthalmology research and development company. Its lead product, Squalamine,
is currently being studied as an eye drop formulation in several company
sponsored and investigator sponsored phase II clinical trials for various back-of-the-eye
diseases, including wet age-related macular degeneration (wet AMD), retinal
vein occlusion, diabetic macular edema and proliferative diabetic retinopathy.
The company’s second product, OHR/AVR118, is designed to treat cancer cachexia,
which is commonly known as wasting syndrome. Through these two candidates,
Ohr’s product pipeline offers a new ray of hope to patients suffering from
these devastating diseases.
Unlike current wet AMD treatment
options, which are administered via injection directly into the eye, Ohr’s
innovative Squalamine formulation is designed for self-administration,
eliminating the need for painful intravitreal injections and providing a
significant cost advantage, as compared to the current standards of care.
According to a report by the National Eye Institute, wet AMD is a common eye
condition and a leading cause of vision loss among people aged 50 and older,
affecting over 1.75 million patients in the United States alone. Through the
development of Squalamine, Ohr could effectively revolutionize the standard
treatment option for this condition, creating a formidable platform to realize
significant growth in the ophthalmology market.
In addition to Squalamine, Ohr
is addressing a vastly underserved market through the continued development of
OHR/AVR118 for the treatment of cancer cachexia. Cancer cachexia is a severe
wasting disorder characterized by a significant loss of appetite, weight loss,
fatigue, weakness and muscle atrophy. Currently, there is no FDA approved drug
for the treatment of this debilitating condition, providing Ohr with another
opportunity to realize sustainable increases in shareholder returns.
With a product pipeline
including two unique drug candidates in four distinctive indications currently
undergoing phase II clinical trials, Ohr is continuing to set the stage for
rapid increases in market share in the years to come. For prospective
investors, this progress makes Ohr an intriguing option moving forward.
For more information, visit
www.ohrpharmaceutical.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
